Picture of Sinopharm logo

1099 — Sinopharm News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareBalancedLarge CapContrarian

Medical products distributor Sinopharm Group's prelim 9-month revenue slips

Medical products distributor Sinopharm Group's prelim 9-month revenue slips


Overview

  • China pharmaceutical distributor's preliminary 9-month revenue fell 0.11% yr/yr

  • Preliminary 9-month net profit attributable to shareholders down 0.48% yr/yr


Outlook

  • Company will focus on new growth drivers and improving operational quality and profitability


Result Drivers

  • DISTRIBUTION SEGMENT - Co said narrowing revenue decline and profit growth in distribution segment reflected operational resilience

  • RETAIL SEGMENT - Co attributed retail segment profit growth to product mix optimization, store network adjustments and expense control


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

RMB 5.51 bln

9M Net profit attributable to
shareholders of the listed
company

RMB 95.25 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Sinopharm Group Co Ltd is HK$20.80, about 35.3% above its October 20 closing price of HK$15.37

  • The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago


Reuters Recommended Reads

  • Oct 20 - China Mobile's nine-month profit falls 7.9% on higher costs

  • Oct 19 - China's economic growth picks up as exports boom, consumers balk

  • Oct 19 - China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Sinopharm

See all news